NCT00002089已完成不适用
An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 试验地点
- 1
研究概览
简要总结
To evaluate the efficacy and safety of azithromycin given chronically for the treatment of Mycobacterium avium (MAC) bacteremia in patients failing or intolerant of current available MAC therapy.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Day 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Disseminated MAC as defined by current (within the last month) positive blood, bone marrow, or liver biopsy culture for MAC, and considered symptomatic (fever, night sweats, anorexia, weight loss, fatigue, or malaise).
- •At least 2 months of prior treatment with available combination MAC therapy or less than 2 months of such accompanied by unacceptable adverse effects.
- •Life expectancy of more than 2 weeks.
- •Approval of eligibility from Pfizer Clinical Monitor.
- •Consent of parent or guardian if under legal age of consent.
- •Patients who have completed acute treatment with azithromycin for MAC in protocol 066-131 or 066-148 will be exempt from inclusion criteria 1 and 2 and can continue therapy through this protocol if their physician feels they have benefitted from prior azithromycin therapy.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms and conditions are excluded:
- •Known hypersensitivity or intolerance to macrolide antibiotics.
- •Inability to take oral medications or current condition that is likely to interfere with absorption (e.g., gastrectomy).
- •Concurrent Medication:
- •Other MAC therapy instituted during the first 2 months of the study.
- •Other investigational drugs, with the exception of those available through a Treatment IND program.
- •Patients with the following prior conditions are excluded:
- •History of hypersensitivity or intolerance to azithromycin.
- •Prior Medication:
- •Other investigational drugs within 7 days of enrollment, with the exception of Treatment IND drugs (such as ddC).
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Azithromycin in the Treatment of M. Avium Complex Lung DiseaseMycobacterium Avium Complex Lung DiseaseNCT00599079The University of Texas Health Science Center at Tyler66
已完成
4 期
Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's DiseaseCrohn's DiseaseNCT01596894Prof. Arie Levine73
已完成
不适用
Efficacy of Azithromycin as an Adjunct to Non-Surgical Periodontal TreatmentPeriodontitisNCT03629288Universidad Nacional Andres Bello18
已完成
不适用
A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available TherapyMycobacterium Avium-Intracellulare InfectionTuberculosis, Mycobacterium InfectionHIV InfectionsNCT00002085Pfizer
Unknown
4 期
Azithromycin in Hospitalized COVID-19 PatientsCOVID-19NCT04359316Shahid Beheshti University of Medical Sciences40